Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Bullock

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 25, 2009
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial)Clive Ballard, Richard Brown, Jane Fossey, et al.
The Lancet. Neurology|December 2, 2008
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trialAlistair Burns, Roberto Bernabei, Roger Bullock, et al.
Frontiers in Aging Neuroscience|April 10, 2014
Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailtyPhilippe H Robert, Alexandra König, Hélene Amieva, et al.
The New England Journal of Medicine|October 5, 2007
Donepezil for the treatment of agitation in Alzheimer's diseaseRobert J Howard, Edmund Juszczak, Clive G Ballard, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
The New England Journal of Medicine|January 25, 2018
Trial of Solanezumab for Mild Dementia Due to Alzheimer's DiseaseLawrence S Honig, Bruno Vellas, Michael Woodward, et al.
Journal of Psychopharmacology (Oxford, England)|October 25, 2006
Clinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyAlistair Burns, John O'Brien, , et al.
Dementia and Geriatric Cognitive Disorders|November 8, 2007
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part IPauline Aalten, Frans R J Verhey, Marina Boziki, et al.
Dementia and Geriatric Cognitive Disorders|November 21, 2007
Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part IIPauline Aalten, Frans R J Verhey, Marina Boziki, et al.
Alzheimer'S Research & Therapy|March 28, 2015
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic reviewKatrin Jekel, Marinella Damian, Carina Wattmo, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 25, 2009
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial)Clive Ballard, Richard Brown, Jane Fossey, et al.
The Lancet. Neurology|December 2, 2008
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trialAlistair Burns, Roberto Bernabei, Roger Bullock, et al.
Frontiers in Aging Neuroscience|April 10, 2014
Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailtyPhilippe H Robert, Alexandra König, Hélene Amieva, et al.
The New England Journal of Medicine|October 5, 2007
Donepezil for the treatment of agitation in Alzheimer's diseaseRobert J Howard, Edmund Juszczak, Clive G Ballard, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
The New England Journal of Medicine|January 25, 2018
Trial of Solanezumab for Mild Dementia Due to Alzheimer's DiseaseLawrence S Honig, Bruno Vellas, Michael Woodward, et al.
Journal of Psychopharmacology (Oxford, England)|October 25, 2006
Clinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyAlistair Burns, John O'Brien, , et al.
Dementia and Geriatric Cognitive Disorders|November 8, 2007
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part IPauline Aalten, Frans R J Verhey, Marina Boziki, et al.
Dementia and Geriatric Cognitive Disorders|November 21, 2007
Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part IIPauline Aalten, Frans R J Verhey, Marina Boziki, et al.
Alzheimer'S Research & Therapy|March 28, 2015
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic reviewKatrin Jekel, Marinella Damian, Carina Wattmo, et al.
Pageof 7